您的位置：首页 → 单机游戏 → 角色扮演 → 怪物猎人世界新装备介绍怪物猎人世界新装备新系统一览

法证先锋2

Chinese film “Niu Lai” turns viral flop into box-office hit_我的网站

巨星秀

A | (ECNS) -- The animated film Niu Lai has become an unlikely sensation after its daily box office of just 7,352 yuan ($1,020) sparked a trending hashtag and drew audiences curious to see “how bad it could be.” By Wednesday afternoon, the film had grossed 25.72 million yuan, with the ma jor Chinesefilm data and box-office tracking platform Lighthouse raising its projection to more than 89.34 million yuan. Created over five years by director Xin Yumeng and her mother Sun Lifang without professional training or outside support, the 86-minute film features crude animation and stiff movements that became its biggest draw. Clips shared online fueled viral exposure, sending Maoyan’s “want to see” count from 300 to 57,000 in a single day. The title Niu Lai — a pun on “bull market coming” — resonated with investors amid stock market volatility. A scene of a calf tripping and smiling oddly was turned into a meme linked to “semiconductors,” making the character a mascot for traders. Some investors even coordinated seat purchases to spell out the Chinese character for “bull” in cinemas. The film’s popularity illustrates how audiences are increasingly buying into an online cultural phenomenon rather than simply a movie. Niu Lai is also reportedly preparing for overseas release, with Singapore expected to be its first international market. (By Gong Weiwei) 。 8月13日，钱塘生物医药产业再迎里程碑时刻。位于杭州医药港的天境生物（TJ Biopharma）宣布，其产品注射用菲泽妥单抗（商品名：境斐®）正式获得国家药品监督管理局批准上市，用于与来那度胺和地塞米松联合用药，治疗既往至少接受过一线治疗的多发性骨髓瘤成年患者。这是该产品在全球范围内的首次获批。

B | 境斐®是一款靶向CD38的人源单克隆抗体，由天境生物在中国完成了多发性骨髓瘤适应症的临床开发与注册申报。今年4月，该企业与全球生物制药巨头渤健达成战略合作，渤健获得该产品大中华区独家权益，交易总金额达8.5亿美元。这一合作也标志着渤健实现了菲泽妥单抗全球权益的统一。根据协议，渤健将负责商业化，天境生物则依托其位于杭州医药港的GMP生产基地负责商业化供药。该基地已取得药品生产许可证，可实现核心产品的本土化稳定供应。

C | “十年前，这些产品要等在国外上市了，再引进到中国重新做开发。目前，我们自主研发的产品把权益授权给海外公司。”天境生物董事长钱丽丽此前在接受央视《焦点访谈》采访时所说，从“引进来”到“授权出海”，钱塘创新药正完成角色的根本转换。

D | 境斐®的获批，也意味着今年以来钱塘已有3款1类创新药上市，数量位居全省第一。从“年年都有创新药”的目标提出，到如今多款产品密集落地，这一愿景正在钱塘一步步成为现实。截至目前，杭州医药港已集聚生物医药企业1800余家，累计4款1类创新药获批上市。另有138个创新药进入临床试验，数量居杭州市首位，其中14个药品处于临床三期。

E |

Current article:http://d2a3b0.yofateeikengyeche.cfd/igvy5w/20260826/4230716.html

Published on:04:47:44

文章评论

查看所有0条评论>>